NYSE:MRK 20 December 2025 - 31 December 2025

Merck & Co shares were down 0.1% at $106.68 in midday trading on Monday, showing relative resilience as U.S. stocks drifted lower in thin year-end trade. The S&P 500-linked SPDR ETF fell 0.6% and the Nasdaq-100 tracker slid 0.7%.

Merck & Co., Inc. heads into the final trading days of 2025 with shares hovering near fresh highs after a late-December climb that has put the pharmaceutical giant back in the spotlight for both defensive investors and catalyst-driven traders. With U.S. stock markets closed for the weekend, attention shifts to what could shape MRK when the regular session resumes Monday—ranging from year-end positioning and Fed expectations to analyst outlooks focused on Merck’s ability to grow beyond Keytruda. Reuters

As of 10:40 p.m. ET in New York on Friday, Dec. 26, 2025, U.S. markets have wrapped up the post-Christmas session and are heading into a weekend — leaving investors to digest a fresh cluster of headline catalysts around Merck & Co., Inc. before the next opening bell.

U.S. stock markets were closed for Christmas Day and are scheduled to reopen Friday, Dec. 26 after a holiday-early close on Wednesday, Dec. 24. New York Stock Exchange

December 25, 2025 — Merck & Co., Inc. is ending 2025 with something investors tend to enjoy: momentum with a story behind it. Even with U.S. markets closed for Christmas Day, Merck shares are in focus after a late-December climb that pushed the stock to fresh highs, helped along by a major Wall Street upgrade and a burst of pipeline and regulatory headlines. MarketBeat

Merck & Company, Inc. stock is ending 2025 on a strong note. On December 24, 2025, shares of Merck pushed to a fresh 12‑month high around the $106 level, extending a powerful late‑year rally that has put the pharma bellwether back in the spotlight. MarketBeat+2Investing.com+2

Merck & Co., Inc. is closing in on year-end with a rare mix of policy-driven headlines, regulatory acceleration, and pipeline catalysts that are shaping investor expectations for 2026 and beyond. From a White House-backed drug-pricing framework that offers tariff relief to drugmakers, to the FDA’s fast-track voucher program attaching itself to two Merck assets with blockbuster potential, MRK stock is being evaluated not just on quarterly numbers—but on whether Merck can extend growth beyond Keytruda while navigating intensifying U.S. drug-pricing scrutiny. Reuters+2Reuters+2